TY - JOUR
AU1 - Sölétormos,, G
AU2 - Nielsen,, D
AU3 - Schiøler,, V
AU4 - Skovsgaard,, T
AU5 - Dombernowsky,, P
AB - Abstract We investigated whether model systems integrating stochastic variation into criteria for marker assessment could be used for monitoring metastatic breast cancer. A total of 3989 serum samples was obtained from 204 patients receiving first-line chemotherapy and from 112 of these patients during follow-up. Each sample was analyzed for cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen. The efficiency for identifying progression and nonprogression was 94% during therapy and 85% during follow-up, with no false-positive marker results for progressive disease. At clinical progressive disease, the median positive lead time was 35 days during therapy and 76 days during follow-up. Tumor marker assessment may document that a therapy is effective and ought to be continued in spite of adverse toxic effects, and that a treatment is ineffective and should be stopped to prevent unnecessary toxicity. Marker information may also be useful in studies investigating whether early treatment during follow-up will alter the prognosis of metastatic breast cancer. This content is only available as a PDF. © 1996 The American Association of Clinical Chemists, Inc. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
TI - Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up
JF - Clinical Chemistry
DO - 10.1093/clinchem/42.4.564
DA - 1996-04-01
UR - https://www.deepdyve.com/lp/oxford-university-press/tumor-markers-cancer-antigen-15-3-carcinoembryonic-antigen-and-tissue-nte0Ne2JI3
SP - 564
EP - 575
VL - 42
IS - 4
DP - DeepDyve
ER -